Physician profile
Michael H Gordon
NPI 1043288897
$1,276.31
in general payments reported to CMS, 2019-2025
26 companies · $99.08 in 2025
The $99.08 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $105 · 2021: $151 · 2022: $267 · 2023: $386 · 2024: $69.77 · 2025: $99.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $554.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $228.91 | 2019-2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $109.96 | 2019-2022 | |
| Amgen INC. | $107.24 | 2019-2025 | Otezla, Repatha |
| Pfizer INC. | $94.18 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.69 | 2019-2024 | Jardiance, Tradjenta |
| Lilly USA, LLC | $77.41 | 2020-2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $67.63 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $52.34 | 2021-2023 | Trintellix |
| Amarin Pharma, INC. | $41.85 | 2019 | |
| Exact Sciences Corporation | $40.97 | 2023 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $33.47 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $31.33 | 2021-2022 | |
| Abbvie INC. | $30.23 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $29.15 | 2021-2023 | Xarelto |
| Almatica Pharma LLC | $28.60 | 2024-2025 | Loreev Xr |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.27 | 2020-2023 | Xifaxan |
| Sanofi Pasteur INC. | $25.77 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $25.43 | 2022-2023 | Farxiga |
| Avanir Pharmaceuticals, INC. | $24.80 | 2022 | |
| Abiomed | $19.32 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.94 | 2024 | |
| Axsome Therapeutics, INC. | $18.33 | 2023 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $17.74 | 2023 | Rexulti |
| Glaxosmithkline, LLC. | $16.43 | 2023 | Trelegy Ellipta |
| Aimmune Therapeutics, INC. | $16.34 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.